Evidence map›Paper›PMID 37469801›Full record

ArticleHemaSphere2023

Context-dependent T-cell Receptor Gene Repertoire Profiles in Proliferations of T Large Granular Lymphocytes.

Jorn L J C Assmann, Elisavet Vlachonikola, Pieter M Kolijn, Andreas Agathangelidis, Nikolaos Pechlivanis, Apostolia Papalexandri, Kostas Stamatopoulos, Anastasia Chatzidimitriou, Anton W Langerak

Open access · goldAbstract read
In one paragraph

Article in HemaSphere, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Jorn L J C AssmannLaboratory for Medical Immunology, Department of Immunology, Erasmus MC, Rotterdam, Netherlands.
Elisavet VlachonikolaInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Greece.
Pieter M KolijnLaboratory for Medical Immunology, Department of Immunology, Erasmus MC, Rotterdam, Netherlands.
Andreas AgathangelidisInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Greece.
Nikolaos PechlivanisInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Greece.
Apostolia PapalexandriHematology Department and HCT Unit, Papanicolaou Hospital, Thessaloniki, Greece.
Kostas StamatopoulosInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Greece.
Anastasia ChatzidimitriouInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Greece.
Anton W LangerakLaboratory for Medical Immunology, Department of Immunology, Erasmus MC, Rotterdam, Netherlands.
Centre for Research and Technology Hellas · GRErasmus MC · NLG. Papanikolaou General Hospital · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T cell large granular lymphocyte (T-LGL) lymphoproliferations constitute a disease spectrum ranging from poly/oligo to monoclonal. Boundaries within this spectrum of proliferations are not well established. T-LGL lymphoproliferations co-occur with a wide variety of other diseases ranging from autoimmune disorders, solid tumors, hematological malignancies, post solid organ, and hematopoietic stem cell transplantation, and can therefore arise as a consequence of a wide variety of antigenic triggers. Persistence of a dominant malignant T-LGL clone is established through continuous STAT3 activation. Using next-generation sequencing, we profiled a cohort of 27 well-established patients with T-LGL lymphoproliferations, aiming to identify the subclonal architecture of the T-cell receptor beta (

Identifiers

PMID37469801
PMCPMC10353713
OpenAlexW4384558942

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.